The drug, SKP-1041, is a new controlled release formulation of a non-benzodiazepine hypnotic agent which utilizes SkyePharma's Geoclock technology. As part of the agreement, SkyePharma will formulate and
The study is designed to enroll over 200 patients with relapsing-remitting MS who have failed earlier treatment with a beta-interferon. Last October the companies entered an agreement to
The charge against the companies, Barr and AstraZeneca, is that they conspired to keep the price of tamoxifen high. With Barr Laboratories being the only distributor of the
The Alzheimer’s Society and drug makers Eisai and Pfizer want to overturn the watchdog’s decision not to approve a group of three drugs known as Aricept, Exelon and
<p>The company's proprietary insomnia agent, NG2-73, an alpha-3 preferring GABA partial agonist, achieved positive top-line results from two dose-ranging, phase 2b clinical trials.<br /><br />Multiple formulations were studied
The drug, TD-5108, is designed to treat chronic constipation and other disorders related to reduced gastrointestinal (GI) motility. Theravance says in the study, all three doses of TD-5108
The studies found that Prozac and Seroxat users developed thinner bones than those who did not take the selective serotonin reuptake inhibitors, or SSRIs. The drugs work by
The company intends to develop pharmaceutical products that use a botanical tobacco component for the treatment of smokeless tobacco dependence, as well as products that would utilize certain
The companies claim that by inhibiting a specific inflammatory process, T-5224 has the potential to block signs and symptoms of rheumatoid arthritis as well as the progressive destruction
Under the terms of the agreement, Yakult gains exclusive commercialization rights to satraplatin and will take the lead in developing the drug in Japan. Yakult will provide an
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.